PDD Shares Have Room to Rise as Worst Already Priced In -- Market Talk
Dow Jones2026/10/30 04:350435 GMT - PDD Holdings' stock has room to rise as the worst has been priced in, according to Deutsche Bank analyst Peter Milliken in a research note. "The company has net cash equivalent to 72% of market cap... the valuation is too attractive for us to look past," DB says. DB's concerns regarding lack of shareholder returns and insufficient transparency remain, the analyst says. The company is coming under regulatory pressure across its key markets which may cap earnings, but substantially lower earnings are priced in, DB says. DB upgrades PDD to buy from hold, with a target price for its ADRs set at US$105.00. Its ADRs last traded at US$79.28. (tracy.qu@wsj.com)
(END) Dow Jones Newswires
October 30, 2026 00:35 ET (04:35 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
BUZZ-3M India shares fall to 19-month low due to quarterly profit decline
Anthropic (ANT.US) to launch IPO roadshow next week, valuation may shrink from 1.5 trillion dollars to 1 trillion dollars! The AI capital feast faces a test.
After the AI sell-off, major investors are questioning whether Anthropic can go public at a $1.5 trillion valuation, or if it will be reduced to around $1 trillion. Fundraising may also decrease from $100 billion to $80 billion.
Crypto prices
More
